• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

早期、无淋巴结转移乳腺癌乳房切除术后哪些患者的疾病会复发?一项系统评价。

Whose Disease Will Recur After Mastectomy for Early Stage, Node-Negative Breast Cancer? A Systematic Review.

作者信息

Kent Collin, Horton Janet, Blitzblau Rachel, Koontz Bridget F

机构信息

Duke University School of Medicine, Durham, NC.

Duke University School of Medicine, Durham, NC; Duke Cancer Institute, Durham, NC.

出版信息

Clin Breast Cancer. 2015 Dec;15(6):403-12. doi: 10.1016/j.clbc.2015.06.008. Epub 2015 Jun 19.

DOI:10.1016/j.clbc.2015.06.008
PMID:26198331
Abstract

Effective local control is associated with improved overall survival, particularly for women with early-stage cancers. No other local therapy is typically offered to women with T1-2 N0 breast cancer after mastectomy, although in select women the 5-year local recurrence rate can be as high as 20%. Therefore, accurately predicting the women who are at highest risk for recurrence after mastectomy will identify those who might benefit from more aggressive adjuvant treatment. A systematic search was conducted identifying risk factors associated with locoregional recurrence, including age, menopausal status, receptor status, lymphovascular invasion (LVI), margin status, use of systemic therapy, size, grade, and genomic classifer score. Although associations varied among studies, the risk factors most consistently identified were age ≤ 40 years, LVI, positive/close margin, and larger tumor size. In women with multiple high risk factors, risk of local recurrence was as high as 20% at 10 years. Additional multicenter studies are needed to investigate risk factors for locoregional recurrence after mastectomy without radiotherapy in T1-2N0 breast cancer. Consideration of additional adjuvant local therapy might be warranted in a subset of women at high risk of local recurrence.

摘要

有效的局部控制与总体生存率的提高相关,尤其是对于早期癌症的女性。对于接受乳房切除术后的T1-2 N0期乳腺癌女性,通常不提供其他局部治疗,尽管在部分女性中,5年局部复发率可能高达20%。因此,准确预测乳房切除术后复发风险最高的女性,将有助于识别那些可能从更积极的辅助治疗中获益的患者。我们进行了一项系统检索,以确定与局部区域复发相关的危险因素,包括年龄、绝经状态、受体状态、淋巴管浸润(LVI)、切缘状态、全身治疗的使用、肿瘤大小、分级和基因组分类评分。尽管不同研究中的关联有所不同,但最一致确定的危险因素是年龄≤40岁、LVI、切缘阳性/切缘接近和肿瘤体积较大。在具有多个高危因素的女性中,10年局部复发风险高达20%。需要开展更多多中心研究,以调查T1-2N0期乳腺癌在未接受放疗的乳房切除术后局部区域复发的危险因素。对于局部复发高危的部分女性,可能有必要考虑额外的辅助局部治疗。

相似文献

1
Whose Disease Will Recur After Mastectomy for Early Stage, Node-Negative Breast Cancer? A Systematic Review.早期、无淋巴结转移乳腺癌乳房切除术后哪些患者的疾病会复发?一项系统评价。
Clin Breast Cancer. 2015 Dec;15(6):403-12. doi: 10.1016/j.clbc.2015.06.008. Epub 2015 Jun 19.
2
Radiotherapy to the chest wall following mastectomy for node-negative breast cancer: a systematic review.阴性淋巴结乳腺癌乳房切除术后胸壁放疗的系统评价
Radiother Oncol. 2009 Apr;91(1):23-32. doi: 10.1016/j.radonc.2008.09.026. Epub 2008 Nov 7.
3
Prophylactic mastectomy for the prevention of breast cancer.预防性乳房切除术用于预防乳腺癌。
Cochrane Database Syst Rev. 2004 Oct 18(4):CD002748. doi: 10.1002/14651858.CD002748.pub2.
4
Post-mastectomy radiotherapy for women with early breast cancer and one to three positive lymph nodes.早期乳腺癌伴 1-3 个阳性淋巴结的女性术后放疗。
Cochrane Database Syst Rev. 2023 Jun 16;6(6):CD014463. doi: 10.1002/14651858.CD014463.pub2.
5
The INTRABEAM® Photon Radiotherapy System for the adjuvant treatment of early breast cancer: a systematic review and economic evaluation.用于早期乳腺癌辅助治疗的INTRABEAM®光子放射治疗系统:系统评价与经济评估
Health Technol Assess. 2015 Aug;19(69):1-190. doi: 10.3310/hta19690.
6
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
7
Axillary treatment for operable primary breast cancer.可手术原发性乳腺癌的腋窝治疗
Cochrane Database Syst Rev. 2017 Jan 4;1(1):CD004561. doi: 10.1002/14651858.CD004561.pub3.
8
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
9
WITHDRAWN: Multi-agent chemotherapy for early breast cancer.撤回:早期乳腺癌的多药联合化疗。
Cochrane Database Syst Rev. 2008 Oct 8;2008(4):CD000487. doi: 10.1002/14651858.CD000487.pub2.
10
Multi-agent chemotherapy for early breast cancer.早期乳腺癌的多药联合化疗
Cochrane Database Syst Rev. 2002(1):CD000487. doi: 10.1002/14651858.CD000487.

引用本文的文献

1
Manganese Porphyrin and Radiotherapy Improves Local Tumor Response and Overall Survival in Orthotopic Murine Mammary Carcinoma Models.锰卟啉与放射治疗改善了原位种植的小鼠乳腺癌模型的局部肿瘤反应和总体生存率。
Radiat Res. 2021 Feb 1;195(2):128-139. doi: 10.1667/RADE-20-00109.1.
2
A multiple breast cancer stem cell model to predict recurrence of T, N breast cancer.多乳腺癌干细胞模型预测 T、N 期乳腺癌复发。
BMC Cancer. 2019 Jul 24;19(1):729. doi: 10.1186/s12885-019-5941-5.
3
Possible benefits from post-mastectomy radiotherapy in node-negative breast cancer patients: a multicenter analysis in Korea (KROG 14-22).
保乳术后放疗对腋窝淋巴结阴性乳腺癌患者的潜在益处:韩国多中心分析(KROG 14-22)
Oncotarget. 2017 Mar 15;8(35):59800-59809. doi: 10.18632/oncotarget.16241. eCollection 2017 Aug 29.
4
Are there patients with T1 to T2, lymph node-negative breast cancer who are "high-risk" for locoregional disease recurrence?是否存在T1至T2期、淋巴结阴性的乳腺癌患者,其局部区域疾病复发的风险为“高风险”?
Cancer. 2017 Jul 15;123(14):2626-2633. doi: 10.1002/cncr.30658. Epub 2017 Mar 23.